SequelSEC

Passage BIO, Inc. PASG

Biological Products, (No Diagnostic Substances) · CIK 0001787297 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$49.30M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Passage BIO, Inc. (PASG) reported net income of -$45.52M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Passage BIO, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Passage BIO, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$49.30M-$70.40M-$108.39M-$138.39M-$185.73M-$112.90M-$37.19M
Net income-$45.52M-$64.77M-$102.06M-$136.12M-$185.39M-$112.23M-$45.63M
Research & development$23.28M$40.18M$61.42MUnavailableUnavailableUnavailable$3.03M
Weighted-average diluted sharesshares 3.17Mshares 3.08Mshares 54.74Mshares 54.43Mshares 53.34Mshares 38.62MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0UnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-14.35$-21.04$-1.86$-2.50$-3.48$-2.91Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$19.88M$24.99M$41.58M$49.34M$60.06M$30.11M$6.95M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Passage BIO, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$46.30M$37.57M$21.71M$34.60M$128.96M$135.00M$158.87M
Total assets$62.28M$102.41M$150.54M$243.55M$355.08M$328.01M$178.61M
Current assets$47.76M$78.82M$117.96M$197.04M$325.07M$317.18M$165.78M
Total liabilities$43.53M$41.15M$39.26M$42.18M$36.42M$23.29M$4.26M
Current liabilities$23.08M$19.36M$16.34M$18.35M$29.50M$21.18M$3.68M
Total equity incl. NCI$18.76M$61.26M$111.28M$201.37M$318.66M$304.71M-$56.25M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$230.60M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.11M$742.00K$1.30M$4.06M$9.45M$5.26M$629.00K

Cash flow

Passage BIO, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$31.51M-$47.96M-$78.26M-$118.21M-$126.88M-$80.52M-$39.90M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$40.22M$54.95M$65.24M$25.20M-$45.81M-$172.11M-$1.69M
Financing cash flow$23.00K$8.87M$135.00K-$1.35M$166.66M$228.75M$175.60M
Net change in cash$8.73M$15.86M-$12.89M-$94.36M-$6.04M-$23.87M$134.01M
Stock-based compensation$3.00M$5.82M$10.92M$18.95M$32.69M$14.58M$1.45M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$728.00K$3.08M$3.72M$3.68M$1.54M$800.00K$134.00K

Derived

Passage BIO, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.07x4.07x7.22x10.74x11.02x14.98x45.04x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PASG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.